General Information of Drug (ID: DML5V76)

Drug Name
MK-4166
Indication
Disease Entry ICD 11 Status REF
Solid tumour/cancer 2A00-2F9Z Phase 1 [1]
Drug Type
Antibody
Cross-matching ID
TTD ID
D0Y2XZ

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Activation-inducible TNFR family receptor (TNFRSF18) TTG6LA7 TNR18_HUMAN Not Available [2]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Solid tumour/cancer
ICD Disease Classification 2A00-2F9Z
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Activation-inducible TNFR family receptor (TNFRSF18) DTT TNFRSF18 2.39E-03 -0.54 -0.7
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

References

1 ClinicalTrials.gov (NCT02132754) Study of MK-4166 in Participants With Advanced Solid Tumors (MK-4166-001). U.S. National Institutes of Health.
2 Immuno-oncology moves beyond PD-1. Nat Biotechnol. 2015 Jul;33(7):673-5.